2024 Q3 Form 10-Q Financial Statement
#000149315224035352 Filed on September 06, 2024
Income Statement
Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
Revenue | $349.0K | $312.4K | |
YoY Change | -52.88% | -48.56% | |
Cost Of Revenue | $233.3K | $333.5K | |
YoY Change | -34.94% | -73.77% | |
Gross Profit | $115.7K | -$21.17K | |
YoY Change | -69.71% | -96.81% | |
Gross Profit Margin | 33.15% | -6.78% | |
Selling, General & Admin | $1.328M | $3.107M | |
YoY Change | -62.93% | 393.21% | |
% of Gross Profit | 1148.31% | ||
Research & Development | $272.0K | $362.7K | |
YoY Change | -37.56% | 43.45% | |
% of Gross Profit | 235.13% | ||
Depreciation & Amortization | $75.83K | $28.11K | |
YoY Change | 169.76% | -45.73% | |
% of Gross Profit | 65.55% | ||
Operating Expenses | $1.601M | $3.470M | |
YoY Change | -60.18% | 293.05% | |
Operating Profit | -$1.485M | -$3.491M | |
YoY Change | -59.19% | 125.68% | |
Interest Expense | -$5.381M | -$1.485M | |
YoY Change | -238.19% | -62.66% | |
% of Operating Profit | |||
Other Income/Expense, Net | -$6.590M | -$268.6K | |
YoY Change | 104.65% | -3169.49% | |
Pretax Income | -$8.074M | -$9.904M | |
YoY Change | 17.74% | 122.14% | |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$8.074M | -$10.54M | |
YoY Change | 17.74% | 115.45% | |
Net Earnings / Revenue | -2313.59% | -3373.1% | |
Basic Earnings Per Share | -$0.22 | ||
Diluted Earnings Per Share | -$0.22 | -$0.33 | |
COMMON SHARES | |||
Basic Shares Outstanding | 37.38M shares | 39.81M shares | 21.73M shares |
Diluted Shares Outstanding | 39.81M shares |
Balance Sheet
Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $3.220K | $81.28K | |
YoY Change | -98.65% | 2000.26% | |
Cash & Equivalents | $3.220K | $81.28K | |
Short-Term Investments | |||
Other Short-Term Assets | $212.5K | $222.6K | |
YoY Change | -17.48% | -13.55% | |
Inventory | $596.9K | $304.9K | |
Prepaid Expenses | |||
Receivables | $144.6K | $151.2K | |
Other Receivables | $0.00 | $0.00 | |
Total Short-Term Assets | $957.3K | $760.1K | |
YoY Change | -38.43% | -38.86% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $78.45K | $84.93K | |
YoY Change | -21.45% | -17.82% | |
Goodwill | $4.728M | ||
YoY Change | |||
Intangibles | $0.00 | ||
YoY Change | -100.0% | ||
Long-Term Investments | $66.03K | $61.88K | |
YoY Change | -7.91% | -2.77% | |
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $6.034M | $289.6K | |
YoY Change | 815.59% | -62.21% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $957.3K | $760.1K | |
Total Long-Term Assets | $6.034M | $289.6K | |
Total Assets | $6.992M | $1.050M | |
YoY Change | 215.81% | -47.77% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.439M | $1.320M | |
YoY Change | 217.15% | 107.21% | |
Accrued Expenses | $3.922M | $3.119M | |
YoY Change | 40.7% | 11.11% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $26.35M | $22.60M | |
YoY Change | 34.74% | 12.43% | |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $44.57M | $33.58M | |
YoY Change | 29.55% | -2.41% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $161.2K | $161.9K | |
YoY Change | -1.62% | 7.91% | |
Other Long-Term Liabilities | $387.8K | $65.52K | |
YoY Change | 299.0% | -53.78% | |
Total Long-Term Liabilities | $549.0K | $227.4K | |
YoY Change | 110.32% | -22.06% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $44.57M | $33.58M | |
Total Long-Term Liabilities | $549.0K | $227.4K | |
Total Liabilities | $45.12M | $33.80M | |
YoY Change | 30.16% | -2.57% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$177.7M | -$169.0M | |
YoY Change | 25.95% | 26.3% | |
Common Stock | $470.8K | $353.7K | |
YoY Change | 160.63% | 158.48% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$38.13M | -$32.75M | |
YoY Change | |||
Total Liabilities & Shareholders Equity | $6.992M | $1.050M | |
YoY Change | 215.81% | -47.77% |
Cashflow Statement
Concept | 2024 Q3 | 2024 Q1 | 2023 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$8.074M | -$10.54M | |
YoY Change | 17.74% | 115.45% | |
Depreciation, Depletion And Amortization | $75.83K | $28.11K | |
YoY Change | 169.76% | -45.73% | |
Cash From Operating Activities | -$1.860M | -$1.132M | |
YoY Change | 340.43% | -20.65% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | ||
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | $0.00 | ||
YoY Change | -100.0% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $0.00 | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $1.782M | 1.208M | |
YoY Change | 169.77% | 0.7% | |
NET CHANGE | |||
Cash From Operating Activities | -$1.860M | -1.132M | |
Cash From Investing Activities | 0.000 | ||
Cash From Financing Activities | $1.782M | 1.208M | |
Net Change In Cash | -$78.06K | 76.01K | |
YoY Change | -133.19% | -133.48% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$1.860M | -$1.132M | |
Capital Expenditures | $0.00 | ||
Free Cash Flow | -$1.860M | -$1.132M | |
YoY Change | 337.33% | -20.65% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
usd | |
CY2023Q4 | PBIO |
Convertible Preferred Share Liability One
ConvertiblePreferredShareLiabilityOne
|
usd | |
CY2023Q4 | PBIO |
Options Payable
OptionsPayable
|
usd | |
CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2024Q1 | PBIO |
Gain On Loan Forgiveness
GainOnLoanForgiveness
|
usd | |
CY2023Q1 | PBIO |
Preferred Stock Issued For Interest
PreferredStockIssuedForInterest
|
usd | |
CY2023Q1 | PBIO |
Preferred Stock For Services
PreferredStockForServices
|
usd | |
CY2023Q1 | PBIO |
Preferred Stock Issued Debt Extensions
PreferredStockIssuedDebtExtensions
|
usd | |
CY2023Q1 | PBIO |
Investment Banker Fees
InvestmentBankerFees
|
usd | |
CY2023Q1 | PBIO |
Increase Decrease In Exchange Account
IncreaseDecreaseInExchangeAccount
|
usd | |
CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
usd | |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
usd | |
CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
usd | |
CY2023Q1 | PBIO |
Preferred Stock Issue With Debt
PreferredStockIssueWithDebt
|
usd | |
CY2023Q1 | PBIO |
Conversion Of Common Stock For Preferred Stock
ConversionOfCommonStockForPreferredStock
|
usd | |
CY2024Q1 | PBIO |
Conversion Of Debt And Interest Into Common Stock
ConversionOfDebtAndInterestIntoCommonStock
|
usd | |
CY2023Q1 | PBIO |
Preferred Stock And Options Issued Acquisition
PreferredStockAndOptionsIssuedAcquisition
|
usd | |
CY2023Q1 | PBIO |
Initial Recognition Of Rou Assets And Liabilities
InitialRecognitionOfRouAssetsAndLiabilities
|
usd | |
CY2023 | us-gaap |
Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
|
usd | |
CY2024Q1 | PBIO |
Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock
|
usd | |
CY2024Q1 | PBIO |
Stock Issued During Period Value Conversion Of Common Stock To Preferred Stock
StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock
|
usd | |
CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
shares | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
shares | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
shares | |
CY2024Q1 | PBIO |
Ub Exchange Account
UbExchangeAccount
|
1181 | usd |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
596404 | usd |
CY2024Q1 | PBIO |
Convertible Preferred Share Liability
ConvertiblePreferredShareLiability
|
1725000 | usd |
CY2024Q1 | PBIO |
Convertible Preferred Share Liability One
ConvertiblePreferredShareLiabilityOne
|
1066800 | usd |
CY2024Q1 | PBIO |
Options Payable
OptionsPayable
|
2210060 | usd |
CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
44569315 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
33576120 | usd |
CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
161182 | usd |
CY2023Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
161864 | usd |
CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
379661 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
60961 | usd |
CY2024Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
8167 | usd |
CY2023Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
4560 | usd |
CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
45118325 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
33803505 | usd |
CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
103 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
102 | usd |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47073892 | shares |
CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47073892 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
35367663 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
35367663 | shares |
CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
470808 | usd |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
353677 | usd |
CY2024Q1 | PBIO |
Warrants To Acquire Common Stock
WarrantsToAcquireCommonStock
|
35684321 | usd |
CY2023Q4 | PBIO |
Warrants To Acquire Common Stock
WarrantsToAcquireCommonStock
|
35684321 | usd |
CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
103453087 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
100236710 | usd |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-177735115 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-169028639 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-38126796 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-32753829 | usd |
CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
6991529 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1049676 | usd |
CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
233310 | usd |
CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
358628 | usd |
CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
272023 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
435646 | usd |
CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
130173 | usd |
CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
226015 | usd |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1198309 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3358056 | usd |
CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
1833815 | usd |
CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
4378345 | usd |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1484558 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3637745 | usd |
CY2024Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
5384991 | usd |
CY2023Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
3893686 | usd |
CY2024Q1 | us-gaap |
Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
|
4155 | usd |
CY2023Q1 | us-gaap |
Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
|
8061 | usd |
CY2024Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-1211511 | usd |
CY2023Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
659277 | usd |
CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2482 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
6259 | usd |
CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-6589865 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3220089 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8074423 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6857834 | usd |
CY2024Q1 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
632053 | usd |
CY2023Q1 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
431807 | usd |
CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8706476 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7289641 | usd |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.22 | |
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.22 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.46 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.46 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39811524 | shares |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39811524 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15839373 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15839373 | shares |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8074423 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6857834 | usd |
CY2023Q1 | PBIO |
Gain On Loan Forgiveness
GainOnLoanForgiveness
|
659277 | usd |
CY2024Q1 | PBIO |
Noncash Lease Expense
NoncashLeaseExpense
|
48561 | usd |
CY2023Q1 | PBIO |
Noncash Lease Expense
NoncashLeaseExpense
|
90279 | usd |
CY2024Q1 | PBIO |
Common Stock And Warrants Issued For Interest
CommonStockAndWarrantsIssuedForInterest
|
1136790 | usd |
CY2023Q1 | PBIO |
Common Stock And Warrants Issued For Interest
CommonStockAndWarrantsIssuedForInterest
|
1705234 | usd |
CY2024Q1 | PBIO |
Preferred Stock Issued For Interest
PreferredStockIssuedForInterest
|
892343 | usd |
CY2024Q1 | PBIO |
Preferred Stock For Services
PreferredStockForServices
|
67500 | usd |
CY2024Q1 | PBIO |
Preferred Stock Issued Debt Extensions
PreferredStockIssuedDebtExtensions
|
1160880 | usd |
CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
75827 | usd |
CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
28114 | usd |
CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1571926 | usd |
CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-615007 | usd |
CY2024Q1 | PBIO |
Common Stock Issued For Debt Extension
CommonStockIssuedForDebtExtension
|
-110310 | usd |
CY2023Q1 | PBIO |
Common Stock Issued For Debt Extension
CommonStockIssuedForDebtExtension
|
-1029939 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
240292 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1430244 | usd |
CY2024Q1 | us-gaap |
Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
|
4155 | usd |
CY2023Q1 | us-gaap |
Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
|
8061 | usd |
CY2024Q1 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
11100 | usd |
CY2023Q1 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
1480944 | usd |
CY2024Q1 | PBIO |
Investment Banker Fees
InvestmentBankerFees
|
210060 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-11718 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
96780 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-58968 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-20338 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-11279 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
25 | usd |
CY2024Q1 | PBIO |
Increase Decrease In Exchange Account
IncreaseDecreaseInExchangeAccount
|
1181 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-225930 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
131729 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-14125 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
101299 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-14464 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-127014 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
867164 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
693653 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1859560 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-422211 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
100000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
81111 | usd |
CY2024Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
2056289 | usd |
CY2023Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
2520000 | usd |
CY2024Q1 | us-gaap |
Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
|
94371 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
|
654681 | usd |
CY2024Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
97052 | usd |
CY2023Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
88200 | usd |
CY2024Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
394229 | usd |
CY2023Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
1628474 | usd |
CY2024Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
8682 | usd |
CY2023Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
99000 | usd |
CY2024Q1 | us-gaap |
Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
|
63300 | usd |
CY2023Q1 | us-gaap |
Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
|
1056149 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1781501 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
660369 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-78059 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
235158 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
81279 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3865 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3220 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
239023 | usd |
CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
324763 | usd |
CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
534872 | usd |
CY2024Q1 | us-gaap |
Stock Issued1
StockIssued1
|
140455 | usd |
CY2023Q1 | us-gaap |
Stock Issued1
StockIssued1
|
1087751 | usd |
CY2024Q1 | PBIO |
Preferred Stock Issue With Debt
PreferredStockIssueWithDebt
|
260000 | usd |
CY2024Q1 | PBIO |
Common Stock Issued In Lieu Of Cash For Dividend
CommonStockIssuedInLieuOfCashForDividend
|
38838 | usd |
CY2023Q1 | PBIO |
Common Stock Issued In Lieu Of Cash For Dividend
CommonStockIssuedInLieuOfCashForDividend
|
102435 | usd |
CY2024Q1 | PBIO |
Noncash Preferred Stock Dividends
NoncashPreferredStockDividends
|
632053 | usd |
CY2023Q1 | PBIO |
Noncash Preferred Stock Dividends
NoncashPreferredStockDividends
|
431807 | usd |
CY2024Q1 | PBIO |
Conversion Of Preferred Stock For Common Stock
ConversionOfPreferredStockForCommonStock
|
69550 | usd |
CY2023Q1 | PBIO |
Conversion Of Preferred Stock For Common Stock
ConversionOfPreferredStockForCommonStock
|
4935 | usd |
CY2024Q1 | PBIO |
Conversion Of Common Stock For Preferred Stock
ConversionOfCommonStockForPreferredStock
|
8750 | usd |
CY2023Q1 | PBIO |
Conversion Of Debt And Interest Into Common Stock
ConversionOfDebtAndInterestIntoCommonStock
|
509033 | usd |
CY2024Q1 | PBIO |
Preferred Stock And Options Issued Acquisition
PreferredStockAndOptionsIssuedAcquisition
|
5959834 | usd |
CY2024Q1 | PBIO |
Initial Recognition Of Rou Assets And Liabilities
InitialRecognitionOfRouAssetsAndLiabilities
|
471155 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-32686371 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
81111 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1430244 | usd |
CY2023 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
431807 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
1419335 | usd |
CY2023 | PBIO |
Issuance Of Common Stock Warrants For Services
IssuanceOfCommonStockWarrantsForServices
|
61609 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
509033 | usd |
CY2023 | PBIO |
Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
|
102435 | usd |
CY2023 | PBIO |
Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
|
1705234 | usd |
CY2023 | PBIO |
Stock Issued During Period Value Common Stock Issued For Debt Extension
StockIssuedDuringPeriodValueCommonStockIssuedForDebtExtension
|
1029939 | usd |
CY2023 | PBIO |
Stock Issued During Period Value Stock Issued With Debt
StockIssuedDuringPeriodValueStockIssuedWithDebt
|
1087751 | usd |
CY2023 | PBIO |
Stock Issued During Period Value Sale Of Common Stock For Cash
StockIssuedDuringPeriodValueSaleOfCommonStockForCash
|
100000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6857834 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-32449321 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-32753829 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-32753829 | usd |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
240292 | usd |
CY2024Q1 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
431709 | usd |
CY2024Q1 | PBIO |
Stock Issued During Period Value Series Cc Stock Dividend
StockIssuedDuringPeriodValueSeriesCCStockDividend
|
200344 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
140455 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
110310 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
11100 | usd |
CY2024Q1 | PBIO |
Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
|
1136790 | usd |
CY2024Q1 | PBIO |
Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
|
38838 | usd |
CY2024Q1 | PBIO |
Stock Issuance Preferred Stock For Services Values
StockIssuancePreferredStockForServicesValues
|
67500 | usd |
CY2024Q1 | PBIO |
Preferred Stock For Debt Extension
PreferredStockForDebtExtension
|
520880 | usd |
CY2024Q1 | PBIO |
Preferred Stock Issued With Debt
PreferredStockIssuedWithDebt
|
260000 | usd |
CY2024Q1 | PBIO |
Preferred Stock For Interest Paidinkind
PreferredStockForInterestPaidinkind
|
807343 | usd |
CY2024Q1 | PBIO |
Preferred Stock Issue For Ub Acquisition
PreferredStockIssueForUbAcquisition
|
1 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8074423 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-38126796 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-38126796 | usd |
CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_843_eus-gaap--UseOfEstimates_zZitMTXl6uU9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zCww6G1VEfgc">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. In addition, estimates were made in projecting future cash flows to quantify impairment of assets, fair value of share based awards and investments in equity securities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> | |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
596404 | usd |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
332875 | usd |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
|
263529 | usd |
CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
596404 | usd |
CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
349000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
741000 | usd |
CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
349000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
741000 | usd |
CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
349000 | usd |
CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
741000 | usd |
CY2024Q1 | us-gaap |
Accounts Receivable Billed For Long Term Contracts Or Programs
AccountsReceivableBilledForLongTermContractsOrPrograms
|
145000 | usd |
CY2023Q4 | us-gaap |
Accounts Receivable Billed For Long Term Contracts Or Programs
AccountsReceivableBilledForLongTermContractsOrPrograms
|
151000 | usd |
CY2024Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
242000 | usd |
CY2023Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
34000 | usd |
CY2024Q1 | PBIO |
Extended Warranty Service
ExtendedWarrantyService
|
242000 | usd |
CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zbEWOJjdqxu3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zZKAF4P3LEx5">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zqYMicoW1Oc8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three months ended March 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zRktLEixLHC3" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeCSFIiVmbPa" style="width: 16%; text-align: right" title="Concentration credit risk percentage">48</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQftjV6uCfe" style="width: 16%; text-align: right" title="Concentration credit risk percentage">64</td><td style="width: 1%; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of March 31, 2024 and December 31, 2023. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5VRO4BsIzGk" style="width: 16%; text-align: right" title="Concentration credit risk percentage">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy9wmQBRtZ8e" style="width: 16%; text-align: right" title="Concentration credit risk percentage">96</td><td style="width: 1%; text-align: left">%</td></tr> </table> <p id="xdx_8A9_znPtiymfNR4f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8706476 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7289641 | usd |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
39811524 | shares |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
39811524 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15839373 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15839373 | shares |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.22 | |
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.22 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.46 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.46 | |
CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
62301281 | shares |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
35909806 | shares |
CY2024Q1 | PBIO |
Forfeiture Rate
ForfeitureRate
|
0.05 | pure |
CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
240292 | usd |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1430244 | usd |
CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
240292 | usd |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1430244 | usd |
CY2024Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
66031 | usd |
CY2023Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
61876 | usd |
CY2024Q1 | PBIO |
Business Combination Recognized Identifiable Fair Value If Options Issued To Finders
BusinessCombinationRecognizedIdentifiableFairValueIfOptionsIssuedToFinders
|
210060 | usd |
CY2024Q1 | PBIO |
Business Combination Expected Time To Maturity
BusinessCombinationExpectedTimeToMaturity
|
P2Y6M | |
CY2024Q1 | PBIO |
Business Combination Annual Risk Free Rate
BusinessCombinationAnnualRiskFreeRate
|
0.0418 | pure |
CY2024Q1 | PBIO |
Business Combination Annualized Volatility
BusinessCombinationAnnualizedVolatility
|
1.03 | pure |
CY2024Q1 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
|
4727976 | usd |
CY2024Q1 | PBIO |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Payables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradePayables
|
734000 | usd |
CY2024Q1 | PBIO |
Business Acquisition Of Stockholders Received
BusinessAcquisitionOfStockholdersReceived
|
127 | shares |
CY2024Q1 | PBIO |
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Preferred Stock
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesPreferredStock
|
2540000 | shares |
CY2024Q1 | us-gaap |
Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
|
4000000 | usd |
CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
180908 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
211852 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
203753 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
158054 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
164133 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
41036 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
959736 | usd |
CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
375189 | usd |
CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
584547 | usd |
CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
48561 | usd |
CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
90279 | usd |
CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y4M2D | |
CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
565409 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
142815 | usd |
CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
204886 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
66895 | usd |
CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
379661 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
60961 | usd |
CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
584547 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
127856 | usd |
CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
32997 | usd |
CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
37810 | usd |
CY2024Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
21737 | usd |
CY2023Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
20850 | usd |
CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
54734 | usd |
CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
58660 | usd |
CY2024Q1 | us-gaap |
Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
|
113100 | usd |
CY2024Q1 | us-gaap |
Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
|
394229 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
|
March, 2020 to March, 2025 | |
CY2024Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
16800000 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
23920432 | usd |
CY2023Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
21329312 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
403060 | usd |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
645471 | usd |
CY2024Q1 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
23517372 | usd |
CY2023Q4 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
20683841 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Stock Price Trigger
DebtInstrumentConvertibleStockPriceTrigger
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | PBIO |
Debt Default Convertible Conversion Ratio
DebtDefaultConvertibleConversionRatio
|
0.75 | pure |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Stock Price Trigger
DebtInstrumentConvertibleStockPriceTrigger
|
2.50 | |
CY2024Q1 | PBIO |
Debt Default Convertible Conversion Ratio
DebtDefaultConvertibleConversionRatio
|
0.75 | pure |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price Decrease
DebtInstrumentConvertibleConversionPriceDecrease
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price Increase
DebtInstrumentConvertibleConversionPriceIncrease
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
|
1 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 | |
CY2024Q1 | PBIO |
Percentage Of Price Rate
PercentageOfPriceRate
|
0.10 | pure |
CY2024Q1 | PBIO |
Convertible Lesser Per Share
ConvertibleLesserPerShare
|
2.5 | |
CY2024Q1 | PBIO |
Convertible Lesser Discount Percent
ConvertibleLesserDiscountPercent
|
0.25 | pure |
CY2024Q1 | us-gaap |
Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
|
0.35 | pure |
CY2024Q1 | PBIO |
Convertible Lesser Per Share
ConvertibleLesserPerShare
|
2.50 | |
CY2024Q1 | PBIO |
Convertible Lesser Discount Percent
ConvertibleLesserDiscountPercent
|
0.25 | pure |
CY2024Q1 | us-gaap |
Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
|
5 | integer |
CY2024Q1 | PBIO |
Convertible Lesser Per Share
ConvertibleLesserPerShare
|
2.50 | |
CY2024Q1 | us-gaap |
Debt Conversion Description
DebtConversionDescription
|
Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders. | |
CY2024Q1 | us-gaap |
Other Borrowings
OtherBorrowings
|
2313930 | usd |
CY2023Q4 | us-gaap |
Other Borrowings
OtherBorrowings
|
1426026 | usd |
CY2024Q1 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
161182 | usd |
CY2023Q4 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
161864 | usd |
CY2024Q1 | us-gaap |
Other Short Term Borrowings
OtherShortTermBorrowings
|
2152748 | usd |
CY2023Q4 | us-gaap |
Other Short Term Borrowings
OtherShortTermBorrowings
|
1264162 | usd |
CY2024Q1 | PBIO |
Convertible Loan
ConvertibleLoan
|
794215 | usd |
CY2024Q1 | us-gaap |
Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
|
700000 | usd |
CY2024Q1 | us-gaap |
Notes Payable
NotesPayable
|
150000 | usd |
CY2024Q1 | PBIO |
Accrued Interest Rate Percent
AccruedInterestRatePercent
|
0.0375 | pure |
CY2024Q1 | us-gaap |
Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
|
731 | usd |
CY2024Q1 | us-gaap |
Principal Transactions Revenue
PrincipalTransactionsRevenue
|
682 | usd |
CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
103 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
102 | usd |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
20628305 | shares |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
18625326 | shares |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
803750 | shares |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
21432055 | shares |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
19148779 | shares |
CY2024Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
5724504 | shares |
CY2024Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P8Y5M8D | |
CY2024Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
0.26 | |
CY2024Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
3571425 | shares |
CY2024Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
|
P7Y10M13D | |
CY2024Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
0.25 | |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
140455 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
110310 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
70000 | shares |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
11100 | usd |
CY2024Q1 | PBIO |
Issuance Of Common Stock For Interest Paidinkind
IssuanceOfCommonStockForInterestPaidinkind
|
1136790 | usd |
CY2024Q1 | PBIO |
Issuance Of Common Stock For Dividends Paidinkind
IssuanceOfCommonStockForDividendsPaidinkind
|
38838 | usd |